As Illumina disappoints Wall Street, competitors make their case at JPM
Last September, Illumina pledged to decipher a person’s genetic code for as little as $200 with its new sequencing machines, part of a wider push to make genetic testing a routine part of check-ups.
At the JP Morgan Healthcare Conference on Wednesday, competitor Element Biosciences said its technology could also sequence a genome for $200 – and potentially with machines that cost less.
“Our goal is to democratize sequencing by driving down costs,” said Element CEO Molly He.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.